Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback